XML 31 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
Acquisitions and License Agreements (Schedule of Reconciliation of Total Consideration) (Details) (USD $)
In Millions, unless otherwise specified
0 Months Ended
Aug. 14, 2014
Mar. 19, 2014
Oct. 01, 2012
Questcor Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Total consideration, net of cash $ 5,470.2mnk_BusinessCombinationConsiderationTransferredNetOfCash
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Plus: cash assumed in acquisition 445.1us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Total consideration 5,915.3us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Less: unpaid purchase consideration (128.8)mnk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedUnpaidPurchaseConsideration
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Less: contingent consideration 0us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Net assets acquired 5,786.5us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= mnk_QuestcorPharmaceuticalsInc.Member
   
Cadence Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Total consideration, net of cash   1,286.0mnk_BusinessCombinationConsiderationTransferredNetOfCash
/ us-gaap_BusinessAcquisitionAxis
= mnk_CadencePharmaceuticalsInc.Member
 
Plus: cash assumed in acquisition   43.2us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= mnk_CadencePharmaceuticalsInc.Member
 
Total consideration   1,329.2us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mnk_CadencePharmaceuticalsInc.Member
 
Less: contingent consideration   0us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= mnk_CadencePharmaceuticalsInc.Member
 
Net assets acquired   1,329.2us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= mnk_CadencePharmaceuticalsInc.Member
 
CNS Therapeutics, Inc.      
Business Acquisition [Line Items]      
Total consideration, net of cash     95.0mnk_BusinessCombinationConsiderationTransferredNetOfCash
/ us-gaap_BusinessAcquisitionAxis
= mnk_CnsTherapeuticsIncMember
Plus: cash assumed in acquisition     3.6us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
/ us-gaap_BusinessAcquisitionAxis
= mnk_CnsTherapeuticsIncMember
Total consideration     98.6us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mnk_CnsTherapeuticsIncMember
Less: contingent consideration     (6.9)us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= mnk_CnsTherapeuticsIncMember
Net assets acquired     $ 91.7us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
/ us-gaap_BusinessAcquisitionAxis
= mnk_CnsTherapeuticsIncMember